Related Experiment Video
Updated: Jul 17, 2026

Application of Fluorescent Nanoparticles to Study Remodeling of the Endo-lysosomal System by Intracellular Bacteria
Published on: January 2, 2015
An inulin-based glycovesicle for pathogen-targeted drug delivery to ameliorate salmonellosis
Yujie Xu1, Congmin Niu2, Shuyi Liang2
1College of Chemistry & Pharmacy, Shaanxi Key Laboratory of Natural Products & Chemical Biology, Northwest A&F University, Yangling 712100, Shaanxi, China.
Abstract:
The gut microbiota plays a significant role in the pathogenesis and remission of inflammatory bowel disease. However, conventional antibiotic therapies may alter microbial ecology and lead to dysbiosis of the gut microbiome, which greatly limits therapeutic efficacy. To address this challenge, novel nanomicelles that couple inulin with levofloxacin via disulfide bonds for the treatment of salmonellosis were developed in this study. Owing to their H2S-responsiveness, the nanomicelles can target the inflamed colon and rapidly release levofloxacin to selectively fight against enteric pathogens. Moreover, the embedded inulin can serve as prebiotic fiber to increase the amount of Bifidobacteria and Lactobacilli in mice with salmonellosis, thus maintaining the intestinal mechanical barrier and regulating the balance of the intestinal flora. Therefore, multifunctional nanomicelles had a better curative effect than pure levofloxacin on ameliorating inflammation in vivo. The pathogen-targeted glycovesicle represents a promising drug delivery platform to maximize the efficacy of antibacterial drugs for the treatment of inflammatory bowel disease.
Insights
Novel nanomicelles delivering levofloxacin and inulin show promise for treating inflammatory bowel disease. These targeted micelles combat pathogens and restore gut bacteria, offering a superior therapeutic effect compared to traditional antibiotics.
Area of Science:
- Gastroenterology
- Microbiology
- Nanotechnology
Background:
- Inflammatory bowel disease (IBD) pathogenesis and remission are linked to gut microbiota composition.
- Conventional antibiotics can disrupt the gut microbiome, leading to dysbiosis and reduced therapeutic efficacy.
- Developing targeted therapies is crucial for effective IBD treatment.
Purpose of the Study:
- To develop novel H2S-responsive nanomicelles coupling inulin with levofloxacin for targeted delivery.
- To evaluate the efficacy of these nanomicelles in treating salmonellosis and ameliorating inflammation in vivo.
- To assess the prebiotic effect of inulin on gut microbiota balance.
Main Methods:
- Synthesis of disulfide-bonded nanomicelles encapsulating inulin and levofloxacin.
- In vivo evaluation in a mouse model of salmonellosis.
- Assessment of bacterial load, gut barrier function, and inflammatory markers.
Main Results:
- The nanomicelles selectively targeted inflamed colonic tissue.
- Levofloxacin release was rapid and pathogen-specific.
- Inulin supplementation increased beneficial Bifidobacteria and Lactobacilli.
- Multifunctional nanomicelles demonstrated superior anti-inflammatory effects compared to free levofloxacin.
Conclusions:
- Pathogen-targeted glycovesicles are a promising drug delivery platform for IBD treatment.
- This approach enhances antibacterial efficacy while modulating the gut microbiome.
- The developed nanomicelles offer a potential strategy to improve IBD management.
More Related Videos
Related Concept Videos
Drug Delivery: Enteral Route
Drugs in...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers

